Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis

UR Kleeberg; S Suciu; EB Brocker; DJ Ruiter; C Chartier; D Lienard; J Marsden; D Schadendorf; Lex Eggermont

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis

UR Kleeberg
, S Suciu
, EB Brocker
, DJ Ruiter
, C Chartier
, D Lienard
, J Marsden
, D Schadendorf
, Lex Eggermont

Surgery

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	390-402
Number of pages	13
Journal	European Journal of Cancer
Volume	40
Issue number	3
Publication status	Published - 2004

Research programs

EMC MM-03-47-11

Cite this

Kleeberg, UR., Suciu, S., Brocker, EB., Ruiter, DJ., Chartier, C., Lienard, D., Marsden, J., Schadendorf, D., & Eggermont, L. (2004). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. European Journal of Cancer, 40(3), 390-402.

@article{70de438360494fec8f8c117f425c8475,

title = "Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis",

author = "UR Kleeberg and S Suciu and EB Brocker and DJ Ruiter and C Chartier and D Lienard and J Marsden and D Schadendorf and Lex Eggermont",

year = "2004",

language = "Undefined/Unknown",

volume = "40",

pages = "390--402",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

number = "3",

}

Kleeberg, UR, Suciu, S, Brocker, EB, Ruiter, DJ, Chartier, C, Lienard, D, Marsden, J, Schadendorf, D & Eggermont, L 2004, 'Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis', European Journal of Cancer, vol. 40, no. 3, pp. 390-402.

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. / Kleeberg, UR; Suciu, S; Brocker, EB et al.
In: European Journal of Cancer, Vol. 40, No. 3, 2004, p. 390-402.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis

AU - Kleeberg, UR

AU - Suciu, S

AU - Brocker, EB

AU - Ruiter, DJ

AU - Chartier, C

AU - Lienard, D

AU - Marsden, J

AU - Schadendorf, D

AU - Eggermont, Lex

PY - 2004

Y1 - 2004

M3 - Article

SN - 0959-8049

VL - 40

SP - 390

EP - 402

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 3

ER -

Kleeberg UR, Suciu S, Brocker EB, Ruiter DJ, Chartier C, Lienard D et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. European Journal of Cancer. 2004;40(3):390-402.